TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multiple Risk Behavior Intervention in Health Care Settings
Brief Summary: This study (aka Healthy Directions2 or HD2) builds on an earlier study titled Healthy Directions (aka Healthy Directions 1 or HD1). HD1 was an intervention designed to target cancer prevention among multi-ethnic populations; it led to significant improvements in the multiple risk behavior score (consumption of red meat, fruits and vegetables, and multi-vitamins). Building on the success of HD1, HD2 further expanded the intervention to include smoking and physical activity. In addition, it expanded the study goals to include increasing efficacy across all target risk behaviors, and promoting long-term maintenance of behavior change.


Options:
A: Intervention Type: BEHAVIORAL; Name: Mammography appointment reminders; telephone counseling; Assigned to Arm(s): N/A
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HD2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: HD2 | Arm Label: HD2+; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: HD2+ | Intervention Type: BEHAVIORAL; Name: HD2; Assigned to Arm(s): HD2 | Intervention Type: BEHAVIORAL; Name: HD2+; Assigned to Arm(s): HD2+
C: Arm Label: Computer Assisted Self Management plus Social Support; Type: EXPERIMENTAL; Interventions: Behavioral: CASM + | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Computer Assisted Self Management; Type: EXPERIMENTAL; Interventions: Behavioral: CASM | Intervention Type: BEHAVIORAL; Name: CASM +; Assigned to Arm(s): Computer Assisted Self Management plus Social Support | Intervention Type: BEHAVIORAL; Name: CASM; Assigned to Arm(s): Computer Assisted Self Management
D: Arm Label: Personal contact (PC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Personal contact (PC) | Arm Label: Interactive technology (IT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interactive technology (IT) | Intervention Type: BEHAVIORAL; Name: Personal contact (PC); Assigned to Arm(s): Personal contact (PC) | Intervention Type: BEHAVIORAL; Name: Interactive technology (IT); Assigned to Arm(s): Interactive technology (IT)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Regular Consumption of a Multiple Micronutrient Fortified Beverage on the Micronutrient Status of Indian Schoolchildren and on Their Mental and Physical Performance
Brief Summary: The purpose of this study is to assess the impact of regular consumption of micronutrient fortified drink in improving nutritional and micronutrient status in Indian school children. The test beverage will be fortified with both, vitamins and minerals.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Lyophilized meat | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Cereal | Intervention Type: OTHER; Name: Lyophilized meat; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Cereal; Assigned to Arm(s): 2
B: Arm Label: Non-Fortified Control Product; Type: PLACEBO_COMPARATOR; Interventions: Other: Non-Fortified Control Product | Arm Label: Micronutrient Fortified Test Product; Type: ACTIVE_COMPARATOR; Interventions: Other: Micronutrient Fortified Test Product | Intervention Type: OTHER; Name: Non-Fortified Control Product; Assigned to Arm(s): Non-Fortified Control Product | Intervention Type: OTHER; Name: Micronutrient Fortified Test Product; Assigned to Arm(s): Micronutrient Fortified Test Product
C: Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nutritional supplement; Type: EXPERIMENTAL; Interventions: Other: Nutritional supplement | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: OTHER; Name: Nutritional supplement; Assigned to Arm(s): Nutritional supplement | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Micronutrient (Zinc and Iron) fortification; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Pre and Probiotic fortification; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Heart Failure Center Program on The Progression of Biomarkers, Changes in Life Quality, Left Ventricular Ejection Fraction, and Cardiac Outcomes in Patients With Congestive Heart Failure
Brief Summary: Congestive heart failure (CHF) is a major public health problem worldwide. CHF carries a devastating prognosis, which resembles that of some types of malignant cancer. Despite substantial improvements in the management of the disease, the prognosis remains poor especially in advanced stages of the disease. For these patients, self-management plan includes monitoring of symptoms such as fatigue and shortness of breath, daily weighing, and knowing what to do if signs of deterioration appear, and when to report the changes to health. The investigators hypothesize that patients in the heart failure management programs that promote self-management by means of intensive education, edema index-assistance, and telephone follow-up can improve their functional status and quality of life, as well as the biomarkers of CHF, left ventricular systolic function, proteinuria and nutritional status.


Options:
A: Arm Label: Comprehensive Geriatric Assessment; Type: EXPERIMENTAL; Interventions: Other: Comprehensive Geriatric Assessment | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Comprehensive Geriatric Assessment; Assigned to Arm(s): Comprehensive Geriatric Assessment
B: Arm Label: control group; Type: N/A; Interventions: N/A | Arm Label: Case management group; Type: N/A; Interventions: N/A
C: Arm Label: standard course; Type: OTHER; Interventions: Other: pharmacist-led standardized medication review | Arm Label: pharmacist-led standardized medication review; Type: OTHER; Interventions: Other: pharmacist-led standardized medication review | Intervention Type: OTHER; Name: pharmacist-led standardized medication review; Assigned to Arm(s): pharmacist-led standardized medication review, standard course
D: Arm Label: Shed-Meds: A Patient-Centered Deprescribing Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Shed-Meds: A Patient-Centered Deprescribing Intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shed-Meds: A Patient-Centered Deprescribing Intervention; Assigned to Arm(s): Shed-Meds: A Patient-Centered Deprescribing Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Anti-Arrhythmic Medication (Amiodarone) Post Surgical Ablation for Atrial Fibrillation - Is it Necessary?
Brief Summary: The purpose of this study is to determine whether anti arrhythmic medication, specifically Amiodarone, is required during the first three months post surgical ablation.

Hypothesis: Amiodarone will not be required during the first three months as verified by no increase in rehospitalizations for recurrent Atrial Fibrillation, and report of sinus rhythm at surgical follow up (approximately 3 weeks from date of surgery), 6 weeks and 12 weeks to include patients' first follow up with cardiologist at approximately 3 months post surgery.


Options:
A: Arm Label: Dormant PV conduction; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Additional ablation until elimination of dormant conduction, Procedure: No additional ablation | Arm Label: No dormant PV conduction; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Registry group, Procedure: Usual medical care | Intervention Type: PROCEDURE; Name: Additional ablation until elimination of dormant conduction; Assigned to Arm(s): Dormant PV conduction | Intervention Type: PROCEDURE; Name: No additional ablation; Assigned to Arm(s): Dormant PV conduction | Intervention Type: PROCEDURE; Name: Registry group; Assigned to Arm(s): No dormant PV conduction | Intervention Type: PROCEDURE; Name: Usual medical care; Assigned to Arm(s): No dormant PV conduction
B: Arm Label: AAD:YES; Type: OTHER; Interventions: Drug: propafenone; flecainide; sotalol; dofetilide, Device: Radiofrequency catheter ablation | Arm Label: AAD:NO; Type: OTHER; Interventions: Device: Radiofrequency catheter ablation | Intervention Type: DRUG; Name: propafenone; flecainide; sotalol; dofetilide; Assigned to Arm(s): AAD:YES | Intervention Type: DEVICE; Name: Radiofrequency catheter ablation; Assigned to Arm(s): AAD:NO, AAD:YES
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amiodarone | Arm Label: Study; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amiodarone | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): Study
D: Arm Label: No Amiodarone; Type: ACTIVE_COMPARATOR; Interventions: Other: No Amiodarone | Arm Label: Amiodarone; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: No Amiodarone; Assigned to Arm(s): No Amiodarone

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aliskiren Effect on Plaque Progression In Established Atherosclerosis Using High Resolution 3D MRI (ALPINE): A Double Blind Placebo Controlled Trial
Brief Summary: This study is being done to assess the effectiveness of short term (\~9 months) Aliskiren/Placebo therapy to slow down the progression of atherosclerotic disease in thoracic and abdominal aorta. This will be checked by comparing before and after therapy magnetic resonance imaging (MRI) pictures of the aortic wall. Aliskiren is an FDA approved drug for hypertension but in this study is used for a new indication. Recent studies with animals have shown that Aliskiren therapy reduces the atherosclerotic plaque. Therefore, in this study, the investigators would like to evaluate whether the investigational drug Aliskiren, which is not FDA approved for this indication has the same beneficial effects in people with atherosclerotic disease.


Options:
A: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A
B: Arm Label: Aliskiren; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aliskiren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
D: Arm Label: Aliskiren; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aliskiren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Vitamin A Supplementation on Disease Activity and Progression in Multiple Sclerotic (MS) Patients
Brief Summary: The aim of this study is the comparison between the effects of supplementation with 25000 IU preformed vitamin A (retinyl palmitate) or placebo for first 6 months and 10000 IU/day for next 6 months on disease activity and progression in patients with Multiple Sclerosis.


Options:
A: Intervention Type: DRUG; Name: Triomar™ (omega-3 fatty acids); Assigned to Arm(s): N/A
B: Arm Label: Polyphenon E 400mg twice a day; Type: EXPERIMENTAL; Interventions: Drug: Polyphenon E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Polyphenon E; Assigned to Arm(s): Polyphenon E 400mg twice a day | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Polyphenon E; Type: EXPERIMENTAL; Interventions: Drug: Polyphenon E | Intervention Type: DRUG; Name: Polyphenon E; Assigned to Arm(s): Polyphenon E
D: Arm Label: vitamin A, multiple sclerosis,; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin A, Drug: Drug: placebo | Arm Label: placebo/Multiple Sclerosis; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin A; Assigned to Arm(s): placebo/Multiple Sclerosis, vitamin A, multiple sclerosis, | Intervention Type: DRUG; Name: Drug: placebo; Assigned to Arm(s): vitamin A, multiple sclerosis,

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study aims to investigate metabolic effects of a standardized green tea extract, containing a defined amount of epigallocatechin-3-gallate (EGCG), in multiple sclerosis patients.


Options:
A: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab
B: Intervention Type: DRUG; Name: Triomar™ (omega-3 fatty acids); Assigned to Arm(s): N/A
C: Arm Label: Polyphenon E; Type: EXPERIMENTAL; Interventions: Drug: Polyphenon E | Intervention Type: DRUG; Name: Polyphenon E; Assigned to Arm(s): Polyphenon E
D: Arm Label: Green tea extract; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Capsules with 160 mg Teavigo (at least 94% EGCG) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Capsules with 160 mg Teavigo (at least 94% EGCG); Assigned to Arm(s): Green tea extract | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Radiographic Progression of Sealed and Infiltrated Caries Lesions in Vivo
Brief Summary: The purpose of this study was to compare with a clinical randomized controlled split-mouth design study the changes in the therapeutic effect of infiltrating versus sealing proximal caries lesions and placebo treatment after 1, 2 and 3 years. The outcome was lesion progression, evaluated by radiographic techniques.


Options:
A: Arm Label: Atraumatic Restorative Treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Atraumatic Restorative Treatment | Arm Label: Hall Technique; Type: EXPERIMENTAL; Interventions: Procedure: Hall Technique | Intervention Type: PROCEDURE; Name: Atraumatic Restorative Treatment; Assigned to Arm(s): Atraumatic Restorative Treatment | Intervention Type: PROCEDURE; Name: Hall Technique; Assigned to Arm(s): Hall Technique
B: Arm Label: SW intervention; Type: EXPERIMENTAL; Interventions: Procedure: SW | Arm Label: DCE intervention; Type: OTHER; Interventions: Procedure: DCE | Intervention Type: PROCEDURE; Name: SW; Assigned to Arm(s): SW intervention | Intervention Type: PROCEDURE; Name: DCE; Assigned to Arm(s): DCE intervention
C: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Device: self assembling peptide P11-4 (Curodont™ Repair), Device: fluoride varnish (Duraphat®) | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Device: fluoride varnish (Duraphat®) | Intervention Type: DEVICE; Name: self assembling peptide P11-4 (Curodont™ Repair); Assigned to Arm(s): intervention | Intervention Type: DEVICE; Name: fluoride varnish (Duraphat®); Assigned to Arm(s): control, intervention
D: Arm Label: Treatment with Infiltrant/Adhesive; Type: EXPERIMENTAL; Interventions: Drug: Resin infiltration / adhesive | Arm Label: Placebo, placebo treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Resin infiltration / adhesive; Assigned to Arm(s): Treatment with Infiltrant/Adhesive | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, placebo treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Intensive and Conventional Exercise Intervention of Nonalcoholic Fatty Liver Disease
Brief Summary: The prevalence of NAFLD is 50-70% in obese people. A decrease of calorie intake and increase of physical activity are recommended as an effective approach for the prevention and treatment of NAFLD. However, the exercise model for NAFLD intervention is understudied. In the present study we aim to compare the effect of intensive and conventional exercise interventions on NAFLD.


Options:
A: Arm Label: Intensive exercise; Type: EXPERIMENTAL; Interventions: Other: Intensive exercise | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Regular exercise; Type: EXPERIMENTAL; Interventions: Other: Conventional exercise | Intervention Type: OTHER; Name: Intensive exercise; Assigned to Arm(s): Intensive exercise | Intervention Type: OTHER; Name: Conventional exercise; Assigned to Arm(s): Regular exercise
B: Arm Label: Polyunsaturated fatty acid (Opti-EPA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyunsaturated fatty acid (Opti-EPA) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Polyunsaturated fatty acid (Opti-EPA); Assigned to Arm(s): Polyunsaturated fatty acid (Opti-EPA) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: treatment group; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E softgel | Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vitamin E softgel; Assigned to Arm(s): treatment group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo group
D: Arm Label: Prebiotic Fibre; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotic fibre, Behavioral: Weight Loss | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo, Behavioral: Weight Loss | Arm Label: Weight Loss; Type: OTHER; Interventions: Behavioral: Weight Loss | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotic fibre; Assigned to Arm(s): Prebiotic Fibre | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Weight Loss; Assigned to Arm(s): Placebo, Prebiotic Fibre, Weight Loss

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Intensive and Conventional Exercise Intervention of Nonalcoholic Fatty Liver Disease
Brief Summary: The prevalence of NAFLD is 50-70% in obese people. A decrease of calorie intake and increase of physical activity are recommended as an effective approach for the prevention and treatment of NAFLD. However, the exercise model for NAFLD intervention is understudied. In the present study we aim to compare the effect of intensive and conventional exercise interventions on NAFLD.


Options:
A: Intervention Type: BEHAVIORAL; Name: Walking 45 mins 2x p.w.; Assigned to Arm(s): N/A
B: Arm Label: Stair walking; Type: EXPERIMENTAL; Interventions: Behavioral: Stair walking | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stair walking | Intervention Type: BEHAVIORAL; Name: Stair walking; Assigned to Arm(s): Control, Stair walking
C: Arm Label: Intensive exercise; Type: EXPERIMENTAL; Interventions: Other: Intensive exercise | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Regular exercise; Type: EXPERIMENTAL; Interventions: Other: Conventional exercise | Intervention Type: OTHER; Name: Intensive exercise; Assigned to Arm(s): Intensive exercise | Intervention Type: OTHER; Name: Conventional exercise; Assigned to Arm(s): Regular exercise
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise - Continuous Walking; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise - Continuous Walking | Arm Label: Exercise - Interval Walking; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Training - Interval Walking | Intervention Type: BEHAVIORAL; Name: Exercise Training - Interval Walking; Assigned to Arm(s): Exercise - Interval Walking | Intervention Type: BEHAVIORAL; Name: Exercise - Continuous Walking; Assigned to Arm(s): Exercise - Continuous Walking

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Intensive and Conventional Exercise Intervention of Nonalcoholic Fatty Liver Disease
Brief Summary: The prevalence of NAFLD is 50-70% in obese people. A decrease of calorie intake and increase of physical activity are recommended as an effective approach for the prevention and treatment of NAFLD. However, the exercise model for NAFLD intervention is understudied. In the present study we aim to compare the effect of intensive and conventional exercise interventions on NAFLD.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low glycemic load diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low fat diet | Intervention Type: BEHAVIORAL; Name: Low glycemic load diet; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low fat diet; Assigned to Arm(s): 2
B: Arm Label: Intensive exercise; Type: EXPERIMENTAL; Interventions: Other: Intensive exercise | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Regular exercise; Type: EXPERIMENTAL; Interventions: Other: Conventional exercise | Intervention Type: OTHER; Name: Intensive exercise; Assigned to Arm(s): Intensive exercise | Intervention Type: OTHER; Name: Conventional exercise; Assigned to Arm(s): Regular exercise
C: Arm Label: Carbohydrate-restricted diet; Type: EXPERIMENTAL; Interventions: Other: Carbohydrate-restricted diet | Arm Label: Control, low-fat diet; Type: ACTIVE_COMPARATOR; Interventions: Other: Control, low-fat diet | Intervention Type: OTHER; Name: Carbohydrate-restricted diet; Assigned to Arm(s): Carbohydrate-restricted diet | Intervention Type: OTHER; Name: Control, low-fat diet; Assigned to Arm(s): Control, low-fat diet
D: Arm Label: Low glycemic index dietary intervention program; Type: ACTIVE_COMPARATOR; Interventions: Other: Low glycemic index dietary intervention program | Arm Label: Simple lifestyle advice; Type: PLACEBO_COMPARATOR; Interventions: Other: simple lifestyle advice | Intervention Type: OTHER; Name: Low glycemic index dietary intervention program; Assigned to Arm(s): Low glycemic index dietary intervention program | Intervention Type: OTHER; Name: simple lifestyle advice; Assigned to Arm(s): Simple lifestyle advice

Answer: B